Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals

scientific article

Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1086/592168
P698PubMed publication ID18855558
P5875ResearchGate publication ID23319479

P50authorKathleen NeuzilQ76169016
Frederick G HaydenQ87843428
Geoffrey J GorseQ89260570
Stefan GravensteinQ90366549
Maria ZambonQ91506671
Janet E McElhaneyQ92876176
Eric A F SimõesQ109845655
P2093author name stringAnn R Falsey
Robert Edelman
Edward E Walsh
Peter F Wright
Eddy Yau
Jose Capellan
Kristen L Nichol
Valérie M-P Sales
P2860cites workMortality associated with influenza and respiratory syncytial virus in the United StatesQ29615578
Influenza-associated hospitalizations in the United StatesQ29619463
Respiratory syncytial virus and parainfluenza virusQ33952428
Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study GroupQ34094440
Progress in the development of respiratory syncytial virus and parainfluenza virus vaccinesQ34285502
Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study GroupQ34358628
Adjuvants for human vaccines--current status, problems and future prospectsQ34373525
Respiratory syncytial virus infection in elderly and high-risk adultsQ34414401
The future of respiratory syncytial virus vaccine developmentQ35632372
Comparison of quantitative reverse transcription-PCR to viral culture for assessment of respiratory syncytial virus sheddingQ35922051
Respiratory syncytial virus infections in previously healthy working adultsQ40597674
Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registryQ43821315
Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adultsQ43979004
Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adultsQ44621708
Serum antibody decay in adults following natural respiratory syncytial virus infectionQ45411871
Experimental infection of humans with A2 respiratory syncytial virusQ45571445
Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopesQ45610521
Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adultsQ45623141
Age related differences in humoral immune response to respiratory syncytial virus infection in adultsQ45644291
Risk factors for severe respiratory syncytial virus infection in elderly personsQ45699277
Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung diseaseQ45732316
Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational studyQ45734830
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderlyQ45760956
Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.Q45765792
Respiratory syncytial virus or influenza?Q45783418
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectinfluenza vaccineQ383260
vaccineQ134808
P304page(s)1317-1326
P577publication date2008-11-01
P1433published inJournal of Infectious DiseasesQ4051141
P1476titleComparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals
P478volume198

Reverse relations

cites work (P2860)
Q45382330A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
Q92310272Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations
Q36606731Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein
Q45326384An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
Q36500189An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice
Q35185596Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection
Q35077892Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice
Q37197103Delta inulin-derived adjuvants that elicit Th1 phenotype following vaccination reduces respiratory syncytial virus lung titers without a reduction in lung immunopathology
Q90668023Development and verification of real-time PCR assay for identification of viral agents causing acute respiratory infections in human beings
Q35986962Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus
Q26782411Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes
Q40134310Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses
Q41553098Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques
Q33601830Enzyme-linked immunospot assay for detection of human respiratory syncytial virus f protein-specific gamma interferon-producing T cells
Q37371036Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations.
Q33555911Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults
Q90681995Impact of Respiratory Syncytial Virus Infection on the Host Cell: Implications for Antiviral Strategies
Q24188037Influenza vaccines for preventing cardiovascular disease
Q54338791Inhibitory effect of potassium alum on smooth muscle contraction of rabbit and its mechanism.
Q45374783Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation
Q90015591Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection
Q33837530Mucosal vaccines against respiratory syncytial virus
Q33489541NGF is an essential survival factor for bronchial epithelial cells during respiratory syncytial virus infection
Q39318498Passive and active immunization against respiratory syncytial virus for the young and old.
Q33776507Pharmacologic advances in the treatment and prevention of respiratory syncytial virus
Q37461377Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response
Q56894869Progress in respiratory virus vaccine development
Q35566601Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years
Q37991125Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients
Q34262180Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice
Q38617302Recent advances in the development of subunit-based RSV vaccines.
Q39118423Respiratory Syncytial Virus Infection: An Illness for All Ages
Q41349182Respiratory syncytial virus infection in older adults: an under-recognized problem
Q56893551Respiratory syncytial virus vaccine development
Q84854616Respiratory syncytial virus vaccine development
Q59354124Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure
Q37572640Strategic priorities for respiratory syncytial virus (RSV) vaccine development
Q37328584Targeting RSV with vaccines and small molecule drugs
Q38630273The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review
Q40933366The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.
Q34222406The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents
Q50120750The role of vaccines in preventing bacterial antimicrobial resistance
Q38140040Translational sciences approach to RSV vaccine development
Q38660842Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.
Q91449694Updates on immunologic correlates of vaccine-induced protection
Q37514757Vaccination against RSV: is maternal vaccination a good alternative to other approaches?
Q45326393Vaccine Prevention of Respiratory Syncytial Virus in Older Adults: The Work Continues
Q39318444Vaccine development for respiratory syncytial virus
Q24201977Vaccines for the common cold
Q38682527Vaccines for the common cold
Q64098587Will Attention by Vaccine Developers to the Host's Nuclear Hormone Levels and Immunocompetence Improve Vaccine Success?

Search more.